ASSURE‐CSU: a real‐world study of burden of disease in patients with symptomatic chronic spontaneous urticaria
Authors:
- Karsten WellerKWKarsten Weller
- Marcus MaurerMMMarcus Maurer
- Clive GrattanCGClive Grattan
- Alla NakonechnaANAlla Nakonechna
- Mohamed AbuzakoukMAMohamed Abuzakouk
- Frédéric BérardFBFrédéric Bérard
- Gordon SussmanGSGordon Sussman
- Ana M. Giménez‐ArnauAGAna M. Giménez‐Arnau
- Javier Ortiz de FrutosJFJavier Ortiz de Frutos
- André KnulstAKAndré Knulst
- G. Walter CanonicaGCG. Walter Canonica
- Kelly HollisKHKelly Hollis
Open Access
- 1 January 2015
- journal article
- research article
- Published by Wiley in Clinical and Translational Allergy
- Vol. 5 (1) , 1-7
Abstract
Background: Chronic spontaneous urticaria (CSU) formerly known as chronic idiopathic urticaria (CIU) is a severe and distressing skin condition that remains uncontrolled in approximately one half of patients, despite the use of licensed, recommended doses of modern, second‐generation H1‐antihistamines. So far, the humanistic, societal and economic burden of CSU/CIU has not been well quantified. Therefore it is important to broaden our understanding of how CSU/CIU impacts patients, society, and healthcare systems, by determining the disease burden of CSU/CIU and the associated unmet need; as well as to further guide the use of new treatments in an efficient and cost‐effective manner.Methods: ASSURE‐CSU is an observational, multicenter study being conducted in the UK, Germany, Canada, France, Italy, Spain, and The Netherlands. The study comprises a retrospective medical chart review in conjunction with patient surveys (including validated tools for assessment of disease impact) and an 8‐day patient diary. The primary objectives of the study are to describe patient demographics, medical history, treatments, and healthcare resource utilization based on medical‐record data and to assess the impact of disease, healthcare resource utilization, work days missed, and productivity loss based on patient‐reported data. Approximately 700 patients (aged ≥18 years) will be enrolled who have CSU/CIU despite currently receiving treatment, and have had persistent symptoms for at least 12 months. Data will be collected retrospectively for the 12 months (±1 month) prior to enrolment wherever possible, and prospectively for the week following enrolment.Discussion: ASSURE‐CSU will be the first study to examine the economic and humanistic burden of disease in patients diagnosed with CSU/CIU who are symptomatic despite treatment. By combining retrospective evaluation of medical records with prospective patient surveys and 8‐day diaries, across seven different countries, the ASSURE‐CSU study will contribute to a better understanding and acknowledgement of the burden of disease in patients with symptomatic chronic spontaneous urticaria.Keywords
Funding Information
- Novartis Pharma AG, Basel Switzerland
This publication has 22 references indexed in Scilit:
- Selected urticaria patients benefit from a referral to tertiary care centres – results of an expert surveyJournal of the European Academy of Dermatology and Venereology, 2011
- The Impact of Chronic Idiopathic Urticaria on Quality of Life in Korean PatientsAnnals of Dermatology, 2009
- How to assess disease activity in patients with chronic urticaria?Allergy, 2008
- Prospective randomized non‐blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticariaJournal of the European Academy of Dermatology and Venereology, 2007
- A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU‐Q2oL)Allergy, 2005
- Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of lifeAnnals of Allergy, Asthma & Immunology, 2004
- The impact of chronic urticaria on the quality of lifeBritish Journal of Dermatology, 1997
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990